Related references
Note: Only part of the references are listed.Single- and Multiple-Dose Pharmacokinetics of Darunavir Plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men
Kevin C. Brown et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts
Brian L. Robbins et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection
Jintanat Ananworanich et al.
PLOS ONE (2012)
A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model
Iart Luca Shytaj et al.
PLOS PATHOGENS (2012)
A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response
Hiroyu Hatano et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-negative Men
Kevin C. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation
Sifei Xing et al.
JOURNAL OF VIROLOGY (2011)
HIV/AIDS RESEARCH Tissue Says Blood Is Misleading, Confusing HIV Cure Efforts
Jon Cohen
SCIENCE (2011)
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
Kristine B. Patterson et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy
D. McMahon et al.
CLINICAL INFECTIOUS DISEASES (2010)
Pharmacologic Opportunities for HIV Prevention
M. R. Nicol et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Differences in HIV Burden and Immune Activation within the Gut of HIV-Positive Patients Receiving Suppressive Antiretroviral Therapy
Steven A. Yukl et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+Cell Infection
Nancie M. Archin et al.
PLOS ONE (2010)
The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
Rajesh T. Gandhi et al.
PLOS MEDICINE (2010)
Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women
Julie B. Dumond et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
J. B. Dinoso et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
Nancy M. Archin et al.
AIDS (2008)
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
LANCET (2008)
HIV integrase inhibitors - Out of the pipeline and into the clinic
Diane V. Havlir
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HIV rebounds from latently infected cells, rather than from continuing low-level replication
Beda Joos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
John M. Murray et al.
AIDS (2007)
Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses
C. B. Hicks et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Beatriz Grinsztejn et al.
LANCET (2007)
Experimental approaches to the study of HIV-1 latency
Yefei Han et al.
NATURE REVIEWS MICROBIOLOGY (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells
Tracy King et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
The survival benefits of AIDS treatment in the United States
Rochelle P. Walensky et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
G Lehrman et al.
LANCET (2005)
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
JM Brenchley et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells
DG Brooks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
